Bringing the Oncology Community Together
Giants of Cancer Care 2015
Researchers Continue to Explore Optimal Use of Radium-223
Limited data exist regarding optimal patient selection and sequencing of radium-223 relative to other approved treatments for patients with metastatic castration-resistant prostate cancer.
Radium-223 Focus of Several Ongoing Combination Studies in mCRPC
A randomized study is underway to determine if the combination of sipuleucel-T (Provenge) and radium-223 (Xofigo) may improve outcomes in patients with metastatic castration-resistant prostate cancer.
Celgene, Juno Ink $1 Billion Immunotherapy Deal
Celgene has entered into a 10-year collaboration with the cellular immunotherapy company Juno Therapeutics, which includes an initial $1 billion payment.
Fluoride PET/CT Scan Could Guide Treatment Selection in Bone Metastatic CRPC
Bone marrow failure may occur following treatment with radium-223 in a portion of patients with metastatic castration-resistant prostate cancer who have high skeletal tumor burden.
Adding Brentuximab Vedotin to R-CHOP Induces 80% Response Rate in DLBCL
Combining the CD30-directed antibody-drug conjugate brentuximab vedotin with R-CHOP yielded objective responses in 80% of patients with advanced DLBCL in a phase II trial.
Novel Combination Strategies Explored in Two Phase III NHL Studies
John P. Leonard, MD, discusses the phase III SELENE and AUGMENT trials, along with smaller investigations, which hope to uncover more efficacious treatments for patients with NHL.
Immunotherapy in Melanoma: What Does the Future Hold?
Howard L. Kaufman, MD, discusses the rapidly advancing immunotherapy armamentarium in melanoma.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.